Abbott lands FDA clearance for Freestyle InsuLinx blood glucose monitoring
Abbott (NYSE:ABT) won 510(k) clearance from the FDA for its FreeStyle InsuLinx blood glucose monitor, its first to include a touch-screen interface, automated logbook and personalization features.
The device, which won CE Mark approval in the European Union in May 2011, will be on the market in the U.S. in the coming months, according to a press release.
The next-generation Freestyle InsuLinx system is USB-compatible and can provider users and caregivers with reminders, messages and reports.
The Abbott Park, Ill.-based health care leviathan was trading 42 cents higher at $57.91 as of about 3 p.m. today. Read more
Avedro files new drug application for VibeX corneal cross-linking treatment
Hospira wins clearance for Symbiq 3.13 infusion pump
Icon Interventional lands CE Mark for Nuloy coronary stent system
